Effects of Long COVID in Patients with Severe Coronavirus Disease 2019 on Long-Term Functional Impairments: A Post Hoc Analysis Focusing on Patients Admitted to the ICU in the COVID-19 Recovery Study II
Abstract
:1. Introduction
2. Methods
2.1. Study Design and Setting
2.2. Study Population and Eligibility Criteria
2.3. Procedures
2.4. Variables and Measurements
2.5. Outcomes
2.6. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Needham, D.M.; Davidson, J.; Cohen, H.; Hopkins, R.O.; Weinert, C.; Wunsch, H.; Zawistowski, C.; Bemis-Dougherty, A.; Berney, S.C.; Bienvenu, O.J.; et al. Improving long-term outcomes after discharge from intensive care unit: Report from a stakeholders’ conference. Crit. Care Med. 2012, 40, 502–509. [Google Scholar] [CrossRef]
- Harvey, M.A.; Davidson, J.E. Postintensive Care Syndrome: Right Care, Right Now… and Later. Crit. Care Med. 2016, 44, 381–385. [Google Scholar] [CrossRef]
- Lee, M.; Kang, J.; Jeong, Y.J. Risk factors for post-intensive care syndrome: A systematic review and meta-analysis. Aust. Crit. Care 2020, 33, 287–294. [Google Scholar] [CrossRef] [PubMed]
- Davis, H.E.; McCorkell, L.; Vogel, J.M.; Topol, E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023, 21, 133–146. [Google Scholar] [CrossRef]
- Li, J.; Zhou, Y.; Ma, J.; Zhang, Q.; Shao, J.; Liang, S.; Yu, Y.; Li, W.; Wang, C. The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID. Signal Transduct. Target Ther. 2023, 8, 416. [Google Scholar] [CrossRef] [PubMed]
- Perlis, R.H.; Lunz Trujillo, K.; Safarpour, A.; Santillana, M.; Ognyanova, K.; Druckman, J.; Lazer, D. Association of Post-COVID-19 Condition Symptoms and Employment Status. JAMA Netw. Open. 2023, 6, e2256152. [Google Scholar] [CrossRef] [PubMed]
- Harris, P.A.; Taylor, R.; Thielke, R.; Payne, J.; Gonzalez, N.; Conde, J.G. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 2009, 42, 377–381. [Google Scholar] [CrossRef]
- ISARIC. ISARIC COVID-19 Follow-Up Study. Available online: https://isaric.org/research/covid-19-clinical-research-resources/covid-19-long-term-follow-up-study-old/ (accessed on 21 June 2024).
- Munari, A.B.; Gulart, A.A.; Araujo, J.; Zanotto, J.; Sagrillo, L.M.; Karloh, M.; Mayer, A.F. Modified Medical Research Council and COPD Assessment Test Cutoff Points. Respir. Care 2021, 66, 1876–1884. [Google Scholar] [CrossRef] [PubMed]
- Zigmond, A.S.; Snaith, R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67, 361–370. [Google Scholar] [CrossRef] [PubMed]
- Itoh, M.; Ujiie, Y.; Nagae, N.; Niwa, M.; Kamo, T.; Lin, M.; Hirohata, S.; Kim, Y. A new short version of the Posttraumatic Diagnostic Scale: Validity among Japanese adults with and without PTSD. Eur. J. Psychotraumatol. 2017, 8, 1364119. [Google Scholar] [CrossRef]
- Igarashi, T. Development of the Japanese version of the three-item loneliness scale. BMC Psychol. 2019, 7, 20. [Google Scholar] [CrossRef] [PubMed]
- Brooks, R.; Group, E. EuroQol: The current state of play. Health Policy 1996, 37, 53–72. [Google Scholar] [CrossRef] [PubMed]
- Muto, Y.; Hosozawa, M.; Hori, M.; Iba, A.; Maruyama, S.; Morioka, S.; Teruya, K.; Nishida, T.; Harada, T.; Yoshida, H.; et al. Post COVID-19 condition in hospitalized survivors after one year of infection during the Alpha- and Delta-variant dominant waves in Japan: COVID-19 Recovery Study II. J. Epidemiol. 2025; epub ahead of print. [Google Scholar]
- World Health Organization. Post COVID-19 Condition (Long COVID). Available online: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition (accessed on 21 June 2024).
- Stickley, A.; Ueda, M. Loneliness in Japan during the COVID-19 pandemic: Prevalence, correlates and association with mental health. Psychiatry Res. 2022, 307, 114318. [Google Scholar] [CrossRef]
- Davydow, D.S.; Hough, C.L.; Langa, K.M.; Iwashyna, T.J. Presepsis depressive symptoms are associated with incident cognitive impairment in survivors of severe sepsis: A prospective cohort study of older Americans. J. Am. Geriatr. Soc. 2012, 60, 2290–2296. [Google Scholar] [CrossRef]
- Yang, T.; Li, Z.; Jiang, L.; Wang, Y.; Xi, X. Risk factors for intensive care unit-acquired weakness: A systematic review and meta-analysis. Acta Neurol. Scand. 2018, 138, 104–114. [Google Scholar] [CrossRef]
- Eastment, M.C.; Berry, K.; Locke, E.; Green, P.; O’Hare, A.; Crothers, K.; Dominitz, J.A.; Fan, V.S.; Shah, J.A.; Ioannou, G.N. BMI and Outcomes of SARS-CoV-2 Among US Veterans. Obesity 2021, 29, 900–908. [Google Scholar] [CrossRef]
- Hatakeyama, J.; Inoue, S.; Liu, K.; Yamakawa, K.; Nishida, T.; Ohshimo, S.; Hashimoto, S.; Kanda, N.; Maruyama, S.; Ogata, Y.; et al. Prevalence and Risk Factor Analysis of Post-Intensive Care Syndrome in Patients with COVID-19 Requiring Mechanical Ventilation: A Multicenter Prospective Observational Study. J. Clin. Med. 2022, 11, 5758. [Google Scholar] [CrossRef] [PubMed]
- Soriano, J.B.; Murthy, S.; Marshall, J.C.; Relan, P.; Diaz, J.V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022, 22, e102–e107. [Google Scholar] [CrossRef]
- Nandasena, H.; Pathirathna, M.L.; Atapattu, A.; Prasanga, P.T.S. Quality of life of COVID 19 patients after discharge: Systematic review. PLoS ONE 2022, 17, e0263941. [Google Scholar] [CrossRef] [PubMed]
- Tziolos, N.R.; Ioannou, P.; Baliou, S.; Kofteridis, D.P. Long COVID-19 Pathophysiology: What Do We Know So Far? Microorganisms 2023, 11, 2458. [Google Scholar] [CrossRef]
- Jeffrey, K.; Woolford, L.; Maini, R.; Basetti, S.; Batchelor, A.; Weatherill, D.; White, C.; Hammersley, V.; Millington, T.; Macdonald, C.; et al. Prevalence and risk factors for long COVID among adults in Scotland using electronic health records: A national, retrospective, observational cohort study. eClinicalMedicine 2024, 71, 102590. [Google Scholar] [CrossRef] [PubMed]
- O’Mahoney, L.L.; Routen, A.; Gillies, C.; Ekezie, W.; Welford, A.; Zhang, A.; Karamchandani, U.; Simms-Williams, N.; Cassambai, S.; Ardavani, A.; et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. eClinicalMedicine 2023, 55, 101762. [Google Scholar] [CrossRef] [PubMed]
- Farinazzo, E.; Ponis, G.; Zelin, E.; Errichetti, E.; Stinco, G.; Pinzani, C.; Gambelli, A.; De Manzini, N.; Toffoli, L.; Moret, A.; et al. Cutaneous adverse reactions after m-RNA COVID-19 vaccine: Early reports from Northeast Italy. J. Eur. Acad. Dermatol. Venereol. 2021, 35, e548–e551. [Google Scholar] [CrossRef] [PubMed]
- Imoto, W.; Yamada, K.; Kawai, R.; Imai, T.; Kawamoto, K.; Uji, M.; Kanda, H.; Takada, M.; Ohno, Y.; Ohtani, H.; et al. A cross-sectional, multicenter survey of the prevalence and risk factors for Long COVID. Sci. Rep. 2022, 12, 22413. [Google Scholar] [CrossRef] [PubMed]
- Blomberg, B.; Mohn, K.G.; Brokstad, K.A.; Zhou, F.; Linchausen, D.W.; Hansen, B.A.; Lartey, S.; Onyango, T.B.; Kuwelker, K.; Saevik, M.; et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 2021, 27, 1607–1613. [Google Scholar] [CrossRef] [PubMed]
- Munblit, D.; Nicholson, T.R.; Needham, D.M.; Seylanova, N.; Parr, C.; Chen, J.; Kokorina, A.; Sigfrid, L.; Buonsenso, D.; Bhatnagar, S.; et al. Studying the post-COVID-19 condition: Research challenges, strategies, and importance of Core Outcome Set development. BMC Med. 2022, 20, 50. [Google Scholar] [CrossRef] [PubMed]
- Gupta, A.; Madhavan, M.V.; Sehgal, K.; Nair, N.; Mahajan, S.; Sehrawat, T.S.; Bikdeli, B.; Ahluwalia, N.; Ausiello, J.C.; Wan, E.Y.; et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020, 26, 1017–1032. [Google Scholar] [CrossRef] [PubMed]
- Nalbandian, A.; Sehgal, K.; Gupta, A.; Madhavan, M.V.; McGroder, C.; Stevens, J.S.; Cook, J.R.; Nordvig, A.S.; Shalev, D.; Sehrawat, T.S.; et al. Post-acute COVID-19 syndrome. Nat. Med. 2021, 27, 601–615. [Google Scholar] [CrossRef] [PubMed]
- Nakanishi, N.; Liu, K.; Kawakami, D.; Kawai, Y.; Morisawa, T.; Nishida, T.; Sumita, H.; Unoki, T.; Hifumi, T.; Iida, Y.; et al. Post-Intensive Care Syndrome and Its New Challenges in Coronavirus Disease 2019 (COVID-19) Pandemic: A Review of Recent Advances and Perspectives. J. Clin. Med. 2021, 10, 3870. [Google Scholar] [CrossRef] [PubMed]
- Inoue, S.; Nakanishi, N.; Amaya, F.; Fujinami, Y.; Hatakeyama, J.; Hifumi, T.; Iida, Y.; Kawakami, D.; Kawai, Y.; Kondo, Y.; et al. Post-intensive care syndrome: Recent advances and future directions. Acute Med. Surg. 2024, 11, e929. [Google Scholar] [CrossRef]
- Galatzer-Levy, I.R.; Huang, S.H.; Bonanno, G.A. Trajectories of resilience and dysfunction following potential trauma: A review and statistical evaluation. Clin. Psychol. Rev. 2018, 63, 41–55. [Google Scholar] [CrossRef]
- Latronico, N.; Peli, E.; Calza, S.; Rodella, F.; Novelli, M.P.; Cella, A.; Marshall, J.; Needham, D.M.; Rasulo, F.A.; Piva, S.; et al. Physical, cognitive and mental health outcomes in 1-year survivors of COVID-19-associated ARDS. Thorax 2022, 77, 300–303. [Google Scholar] [CrossRef] [PubMed]
- Schou, T.M.; Joca, S.; Wegener, G.; Bay-Richter, C. Psychiatric and neuropsychiatric sequelae of COVID-19—A systematic review. Brain Behav. Immun. 2021, 97, 328–348. [Google Scholar] [CrossRef] [PubMed]
- Al-Ramadan, A.; Rabab’h, O.; Shah, J.; Gharaibeh, A. Acute and Post-Acute Neurological Complications of COVID-19. Neurol. Int. 2021, 13, 102–119. [Google Scholar] [CrossRef] [PubMed]
- Ellul, M.A.; Benjamin, L.; Singh, B.; Lant, S.; Michael, B.D.; Easton, A.; Kneen, R.; Defres, S.; Sejvar, J.; Solomon, T. Neurological associations of COVID-19. Lancet Neurol. 2020, 19, 767–783. [Google Scholar] [CrossRef] [PubMed]
- Parravano, M.; Petri, D.; Maurutto, E.; Lucenteforte, E.; Menchini, F.; Lanzetta, P.; Varano, M.; van Nispen, R.M.A.; Virgili, G. Association Between Visual Impairment and Depression in Patients Attending Eye Clinics: A Meta-analysis. JAMA Ophthalmol. 2021, 139, 753–761. [Google Scholar] [CrossRef] [PubMed]
- Steptoe, A.; Wardle, J.; Marmot, M. Positive affect and health-related neuroendocrine, cardiovascular, and inflammatory processes. Proc. Natl. Acad. Sci. USA 2005, 102, 6508–6512. [Google Scholar] [CrossRef]
- Coplan, J.; Andrews, M.; Rosenblum, L.; Owens, M.; Friedman, S.; Gorman, J.; Nemeroff, C. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: Implications for the pathophysiology of mood and anxiety disorders. Proc. Natl. Acad. Sci. USA 1996, 93, 1619–1623. [Google Scholar] [CrossRef] [PubMed]
- Nouraeinejad, A. The pathological mechanisms underlying brain fog or cognitive impairment in long COVID. Int. J. Neurosci. 2024, 134, 812–813. [Google Scholar] [CrossRef] [PubMed]
- Nasserie, T.; Hittle, M.; Goodman, S.N. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw. Open 2021, 4, e2111417. [Google Scholar] [CrossRef]
- Fernández-de-las-Peñas, C.; Palacios-Ceña, D.; Gómez-Mayordomo, V.; Florencio, L.L.; Cuadrado, M.L.; Plaza-Manzano, G.; Navarro-Santana, M. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. Eur. J. Intern. Med. 2021, 92, 55–70. [Google Scholar] [CrossRef] [PubMed]
- Hosey, M.M.; Needham, D.M. Survivorship after COVID-19 ICU stay. Nat. Rev. Dis. Primers 2020, 6, 60. [Google Scholar] [CrossRef] [PubMed]
- Kronbichler, A.; Kresse, D.; Yoon, S.; Lee, K.H.; Effenberger, M.; Shin, J.I. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. Int. J. Infect. Dis. 2020, 98, 180–186. [Google Scholar] [CrossRef]
- Turnbull, A.E.; Rabiee, A.; Davis, W.E.; Nasser, M.F.; Venna, V.R.; Lolitha, R.; Hopkins, R.O.; Bienvenu, O.J.; Robinson, K.A.; Needham, D.M. Outcome Measurement in ICU Survivorship Research From 1970 to 2013: A Scoping Review of 425 Publications. Crit. Care Med. 2016, 44, 1267–1277. [Google Scholar] [CrossRef]
- Berentschot, J.C.; Bek, L.M.; Heijenbrok-Kal, M.H.; van Bommel, J.; Ribbers, G.M.; Aerts, J.; Hellemons, M.E.; van den Berg-Emons, H.J.G.; Group, C.-F.c. Long-term health outcomes of COVID-19 in ICU- and non-ICU-treated patients up to 2 years after hospitalization: A longitudinal cohort study (CO-FLOW). J. Intensive Care 2024, 12, 47. [Google Scholar] [CrossRef]
- Chen, C.; Haupert, S.R.; Zimmermann, L.; Shi, X.; Fritsche, L.G.; Mukherjee, B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J. Infect. Dis. 2022, 226, 1593–1607. [Google Scholar] [CrossRef] [PubMed]
- Flor, N.; Leidi, F.; Casella, F.; Mariani, L.; Piazza, M.; Del Medico, M.; Cogliati, C.B. Two-years chest-CT follow-up after severe COVID-19 pneumonia. Intern. Emerg. Med. 2023, 18, 1243–1245. [Google Scholar] [CrossRef] [PubMed]
- Hatch, R.; Young, D.; Barber, V.; Griffiths, J.; Harrison, D.A.; Watkinson, P. Anxiety, Depression and Post Traumatic Stress Disorder after critical illness: A UK-wide prospective cohort study. Crit. Care. 2018, 22, 310. [Google Scholar] [CrossRef] [PubMed]
- Hatakeyama, J.; Nakamura, K.; Sumita, H.; Kawakami, D.; Nakanishi, N.; Kashiwagi, S.; Liu, K.; Kondo, Y. Intensive care unit follow-up clinic activities: A scoping review. J. Anesth. 2024, 38, 542–555. [Google Scholar] [CrossRef] [PubMed]
- Alashek, W.A.; Ali, S.A. Satisfaction with telemedicine use during COVID-19 pandemic in the UK: A systematic review. Libyan J. Med. 2024, 19, 2301829. [Google Scholar] [CrossRef] [PubMed]
- Cuthbertson, B.H.; Rattray, J.; Campbell, M.K.; Gager, M.; Roughton, S.; Smith, A.; Hull, A.; Breeman, S.; Norrie, J.; Jenkinson, D.; et al. The PRaCTICaL study of nurse led, intensive care follow-up programmes for improving long term outcomes from critical illness: A pragmatic randomised controlled trial. BMJ 2009, 339, b3723. [Google Scholar] [CrossRef] [PubMed]
- Freund, O.; Breslavsky, A.; Givoli-Vilensky, R.; Zacks, N.; Gershman, E.; Melloul, A.; Wand, O.; Bilenko, N.; Bar-Shai, A. Assessment of a close respiratory follow-up schedule at 3 and 6 months after acute COVID-19 and its related investigations. Respir. Med. 2023, 217, 107367. [Google Scholar] [CrossRef] [PubMed]
- Hatakeyama, J.; Nakamura, K.; Inoue, S.; Liu, K.; Yamakawa, K.; Nishida, T.; Ohshimo, S.; Hashimoto, S.; Kanda, N.; Aso, S.; et al. Two-year trajectory of functional recovery and quality of life in post-intensive care syndrome: A multicenter prospective observational study on mechanically ventilated patients with coronavirus disease-19. J. Intensive Care 2025, 13, 7. [Google Scholar] [CrossRef] [PubMed]
- Yong, S.J. Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infect. Dis. 2021, 53, 737–754. [Google Scholar] [CrossRef]
The Survey (n = 220) | |
---|---|
Age, years, median (IQR) | 57 (50, 61) |
Male, n (%) | 157 (71.4) |
BMI, kg/m2, median (IQR) | 27.0 (23.4, 30.3) |
Obesity (BMI ≥ 25 kg/m2), n (%) | 144 (65.5) |
SOFA at ICU admission, median (IQR) | 5 (3, 7) |
Clinical frailty scale, median (IQR) | 2 (1, 3) |
Frailty (clinical frailty scale ≥ 4), n (%) | 4 (1.8) |
ICU mobility scale, median (IQR) | |
day 3 | 0 (0, 1) |
day 5 | 0 (0, 1) |
day 7 | 0 (0, 3) |
Delirium, n (%) | 76 (34.6) |
Duration of delirium, day, median (IQR) | 2 (1, 3) |
MV, n (%) | 157 (71.4) |
Duration of MV, day, median (IQR) | 9 (5, 14) |
HFNC, n (%) | 114 (51.8) |
Length of ICU stay, day, median (IQR) | 9 (5, 14) |
Length of hospital stay, day, median (IQR) | 14.5 (8, 26) |
Comorbidity, n (%) | 132 (60.0) |
Hypertension, n (%) | 62 (28.2) |
Diabetes mellitus, n (%) | 58 (26.4) |
Heart failure, n (%) | 4 (1.8) |
COPD, n (%) | 10 (4.6) |
Cerebrovascular disease, n (%) | 10 (4.6) |
CKD Grade 5, n (%) | 1 (0.5) |
Autoimmune disorder, n (%) | 7 (3.2) |
Immunodeficiency, n (%) | 6 (2.7) |
Mental disorder, n (%) | 10 (4.6) |
Malignant tumor, n (%) | 18 (8.2) |
Prone position, n (%) | 157 (71.4) |
Continuous neuromuscular blockade, n (%) | 91 (41.4) |
ECMO, n (%) | 17 (7.7) |
Duration of ECMO, day, median (IQR) | 9 (7, 12) |
Rehabilitation, n (%) | 187 (85.0) |
Time from ICU admission to rehabilitation program initiation, day, median (IQR) | 3 (2, 4) |
Tracheostomy, n (%) | 30 (13.6) |
RRT, n (%) | 13 (5.9) |
Steroid, n (%) | 218 (99.1) |
Vaccination, n (%) | 190 (86.4) |
Smoking history, n (%) | 138 (62.7) |
Population with mandatory 12-year education, n (%) | 110 (50.0) |
The Survey (n = 220) | |
---|---|
Physical impairments, n (%) | 45 (20.5) |
Mental disorders, n (%) | 77 (35.0) |
Anxiety | 43 (20.0) |
Depression | 57 (25.9) |
PTSD | 33 (15.0) |
Physical impairments or mental disorders, n (%) | 94 (42.7) |
Physical impairments and mental disorders, n (%) | 23 (10.5) |
HADS, mean (SD) | 10.3 (7.8) |
HADS-Anxiety, mean (SD) | 4.9 (3.8) |
HADS-Depression, mean (SD) | 5.2 (4.6) |
PTSD score, mean (SD) | 1.1 (1.6) |
Loneliness, n (%) | 48 (21.8) |
Three-item loneliness scale, mean (SD) | 3.1 (2.4) |
EQ-5D-5L, mean (SD) | 0.831 (0.171) |
Unfair discrimination due to SARS-CoV-2 infection, n (%) | 37 (16.8) |
Living conditions have deteriorated, n (%) | 93 (42.3) |
Changes in the workplace, n (%) | 48 (21.8) |
Changes in employment, n (%) | 33 (15) |
Temporary retirement, n (%) | 8 (3.6) |
Health deterioration due to SARS-CoV-2 infection, n (%) | 7 (3.2) |
Change in occupation, n (%) | 4 (1.8) |
Health deterioration due to SARS-CoV-2 infection, n (%) | 4 (1.8) |
Retirement, n (%) | 16 (7.3) |
Health deterioration due to SARS-CoV-2 infection, n (%) | 12 (5.5) |
Physical Impairments (n = 45) | Non-Physical Impairments (n = 172) | p Value | Mental Disorders (n = 77) | Non-Mental Disorders (n = 133) | p Value | |
---|---|---|---|---|---|---|
Age, yr, median (IQR) | 57 (50, 63) | 56 (50, 61) | 0.41 | 56 (51, 60) | 57 (49, 62) | 0.58 |
Male, n (%) | 28 (62.2) | 127 (73.8) | 0.13 | 56 (72.7) | 95 (71.4) | 0.84 |
BMI, kg/m2, median (IQR) | 27.6 (25.8, 33.1) | 26.7 (23.2, 30.0) | 0.03 | 27.0 (23.5, 30.6) | 26.9 (23.4, 29.9) | 0.51 |
Obesity (BMI ≥ 25 kg/m2), n (%) | 36 (81.8) | 107 (62.2) | 0.01 | 52 (67.5) | 86 (65.2) | 0.73 |
SOFA at ICU admission, median (IQR) | 6 (4, 8) | 4 (3, 7) | 0.02 | 4 (3, 7) | 5 (3, 7) | 0.95 |
Clinical frailty scale, median (IQR) | 2 (1, 3) | 2 (1, 3) | 0.76 | 2 (1, 3) | 2 (1, 3) | 0.73 |
Frailty (CSF ≥ 4), n (%) | 1 (2.7) | 3 (2.2) | 0.85 | 2 (3.0) | 2 (2.0) | 0.68 |
ICU mobility scale, median (IQR) | ||||||
day 3 | 0 (0, 0) | 0 (0, 1) | 0.26 | 0 (0, 1) | 0 (0, 1) | 0.95 |
day 5 | 0 (0, 1) | 0 (0, 1) | 0.41 | 0 (0, 3) | 0 (0, 1) | 0.37 |
day 7 | 0 (0, 3) | 0 (0, 3) | 0.99 | 0 (0, 3) | 0 (0, 3) | 0.86 |
Delirium, n (%) | 18 (40.0) | 58 (33.7) | 0.43 | 29 (37.7) | 45 (33.8) | 0.58 |
Duration of delirium, day, median (IQR) | 2 (1, 3) | 2 (1, 3) | 0.49 | 2 (1, 2) | 2 (1, 4) | 0.15 |
MV, n (%) | 34 (75.6) | 123 (71.5) | 0.59 | 54 (70.1) | 95 (71.4) | 0.84 |
Duration of MV, day, median (IQR) | 13 (6, 26) | 8 (5, 12) | 0.006 | 7.5 (5, 14) | 9 (5, 13) | 0.85 |
HFNC, n (%) | 22 (48.9) | 89 (51.7) | 0.73 | 41 (53.3) | 70 (52.6) | 0.93 |
Length of ICU stay, day, median (IQR) | 11 (7, 26) | 8.5 (5, 13) | 0.01 | 9 (6, 14) | 8 (5, 14) | 0.19 |
Length of hospital stay, day, median (IQR) | 20 (11, 40) | 14 (8, 23.5) | 0.008 | 14 (9, 25) | 15 (8, 24) | 0.65 |
Comorbidity, n (%) | 26 (57.8) | 103 (59.9) | 0.80 | 48 (62.3) | 77 (57.9) | 0.53 |
Hypertension | 9 (20.0) | 52 (30.2) | 0.17 | 26 (33.8) | 33 (24.8) | 0.16 |
Diabetes mellitus | 12 (26.7) | 44 (25.6) | 0.88 | 18 (23.4) | 37 (27.8) | 0.48 |
Heart failure | 1 (2.2) | 3 (1.7) | 0.83 | 2 (2.6) | 2 (1.5) | 0.58 |
COPD | 2 (4.4) | 7 (4.1) | 0.91 | 5 (6.5) | 4 (3.0) | 0.23 |
Cerebrovascular disease | 1 (2.2) | 8 (4.7) | 0.47 | 2 (2.6) | 7 (5.3) | 0.36 |
CKD Grade 5 | 1 (2.2) | 0 (0) | 0.05 | 1 (1.3) | 0 (0) | 0.19 |
Autoimmune disorder | 1 (2.2) | 6 (3.5) | 0.67 | 2 (2.6) | 3 (2.3) | 0.88 |
Immunodeficiency | 2 (4.4) | 4 (2.3) | 0.44 | 1 (1.3) | 4 (3.0) | 0.43 |
Mental disorder | 5 (11.1) | 5 (2.9) | 0.02 | 0 (0) | 9 (6.8) | 0.02 |
Malignant tumor | 2 (4.4) | 16 (9.3) | 0.29 | 4 (5.2) | 13 (9.8) | 0.24 |
Prone position, n (%) | 37 (82.2) | 118 (68.6) | 0.07 | 56 (72.7) | 94 (70.7) | 0.75 |
Continuous neuromuscular blockade, n (%) | 26 (57.8) | 65 (37.8) | 0.02 | 37 (48.1) | 46 (34.6) | 0.05 |
ECMO, n (%) | 7 (15.6) | 10 (5.8) | 0.03 | 5 (6.5) | 12 (9.0) | 0.52 |
Duration of ECMO, day, median (IQR) | 8 (7, 17) | 9.5 (7, 12) | 0.76 | 17 (9, 21) | 8 (6.5, 10.5) | 0.10 |
Rehabilitation, n (%) | 37 (82.2) | 147 (85.5) | 0.59 | 64 (83.1) | 115 (86.5) | 0.51 |
Time from ICU admission to rehabilitation program initiation, day, median (IQR) | 3 (2, 6) | 3 (2, 4) | 0.25 | 3 (2, 5) | 3 (2, 4) | 0.19 |
Tracheostomy, n (%) | 16 (35.6) | 14 (8.1) | <0.01 | 11 (14.3) | 17 (12.8) | 0.76 |
RRT, n (%) | 5 (11.1) | 7 (4.1) | 0.07 | 5 (6.5) | 8 (6.0) | 0.89 |
Steroid, n (%) | 45 (100) | 170 (98.8) | 0.47 | 76 (98.7) | 132 (99.3) | 0.69 |
Vaccination, n (%) | 41 (91.1) | 146 (85.4) | 0.32 | 66 (85.7) | 115 (86.5) | 0.88 |
Smoking history, n (%) | 28 (62.2) | 108 (63.5) | 0.87 | 56 (72.7) | 75 (56.8) | 0.02 |
Population with mandatory 12-year education, n (%) | 32 (71.1) | 75 (44.4) | 0.001 | 42 (55.3) | 60 (45.5) | 0.17 |
From discharge to completion of the survey, day, mean (SD) | 412 (62) | 418 (58) | 0.51 | 417 (60) | 415 (58) | 0.83 |
Long COVID Symptoms, n (%) | Physical Impairments (n = 45) | Non-Physical Impairments (n = 172) | p Value | Mental Disorders (n = 77) | Non-Mental Disorders (n = 133) | p Value |
---|---|---|---|---|---|---|
Long COVID (one or more symptoms) | 43 (95.6) | 127 (73.8) | 0.002 | 64 (83.1) | 99 (74.4) | 0.15 |
Fever | 1 (2.2) | 2 (1.2) | 0.59 | 1 (1.3) | 2 (1.5) | 0.90 |
Fatigue/malaise | 26 (57.8) | 42 (24.4) | <0.001 | 35 (45.5) | 33 (24.8) | 0.002 |
Sore throat | 6 (13.3) | 10 (5.8) | 0.09 | 10 (13.0) | 6 (4.5) | 0.03 |
Rhinorrhea | 3 (6.7) | 9 (5.2) | 0.71 | 4 (5.2) | 7 (5.3) | 0.98 |
Cough | 13 (28.9) | 24 (14.0) | 0.02 | 20 (26.0) | 15 (11.3) | 0.006 |
Dyspnea | 31 (68.9) | 57 (33.1) | <0.001 | 38 (49.4) | 47 (35.3) | 0.046 |
Chest pain | 9 (20.0) | 4 (2.3) | <0.001 | 6 (7.8) | 7 (5.3) | 0.46 |
Palpitations | 15 (33.3) | 18 (10.5) | <0.001 | 19 (24.7) | 14 (10.5) | 0.007 |
Dysgeusia | 4 (8.9) | 21 (12.2) | 0.54 | 11 (14.3) | 12 (9.0) | 0.24 |
Anosmia | 6 (13.3) | 22 (12.8) | 0.92 | 13 (16.9) | 14 (10.5) | 0.19 |
Headache | 6 (13.3) | 17 (9.9) | 0.50 | 12 (15.6) | 10 (7.5) | 0.07 |
Joint pain/joint swelling | 10 (22.2) | 20 (11.6) | 0.07 | 14 (18.2) | 15 (11.3) | 0.16 |
Myalgia | 12 (26.7) | 17 (9.9) | 0.003 | 18 (23.4) | 10 (7.5) | 0.001 |
Muscle weakness | 24 (53.3) | 47 (27.3) | 0.001 | 34 (44.2) | 33 (24.8) | 0.004 |
Anorexia | 2 (4.4) | 6 (3.5) | 0.76 | 3 (3.9) | 6 (4.5) | 0.83 |
Nausea/vomiting | 2 (4.4) | 5 (2.9) | 0.60 | 4 (5.2) | 3 (2.3) | 0.25 |
Abdominal pain | 4 (8.9) | 2 (1.2) | 0.005 | 3 (3.9) | 3 (2.3) | 0.49 |
Sleep disorder | 20 (44.4) | 32 (18.6) | <0.001 | 29 (37.7) | 22 (16.5) | 0.001 |
Decreased concentration | 19 (42.2) | 34 (19.8) | 0.002 | 31 (40.3) | 22 (16.5) | <0.001 |
Brain fog | 12 (26.7) | 21 (12.2) | 0.02 | 20 (26.0) | 13 (9.8) | 0.002 |
Hair loss | 16 (35.6) | 57 (33.1) | 0.76 | 28 (36.4) | 43 (32.3) | 0.55 |
Skin rash | 5 (11.1) | 16 (9.3) | 0.72 | 11 (14.3) | 10 (7.5) | 0.12 |
Eye symptoms | 9 (20.0) | 16 (9.3) | 0.045 | 13 (16.9) | 12 (9.0) | 0.09 |
Dizziness | 9 (20.0) | 8 (4.7) | 0.001 | 11 (14.3) | 6 (4.5) | 0.01 |
Erectile dysfunction/menstrual change | 4 (8.9) | 13 (7.6) | 0.77 | 8 (10.4) | 8 (6.0) | 0.25 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hatakeyama, J.; Nakamura, K.; Aso, S.; Kawauchi, A.; Fujitani, S.; Oshima, T.; Kato, H.; Ota, K.; Kamijo, H.; Asahi, T.; et al. Effects of Long COVID in Patients with Severe Coronavirus Disease 2019 on Long-Term Functional Impairments: A Post Hoc Analysis Focusing on Patients Admitted to the ICU in the COVID-19 Recovery Study II. Healthcare 2025, 13, 394. https://doi.org/10.3390/healthcare13040394
Hatakeyama J, Nakamura K, Aso S, Kawauchi A, Fujitani S, Oshima T, Kato H, Ota K, Kamijo H, Asahi T, et al. Effects of Long COVID in Patients with Severe Coronavirus Disease 2019 on Long-Term Functional Impairments: A Post Hoc Analysis Focusing on Patients Admitted to the ICU in the COVID-19 Recovery Study II. Healthcare. 2025; 13(4):394. https://doi.org/10.3390/healthcare13040394
Chicago/Turabian StyleHatakeyama, Junji, Kensuke Nakamura, Shotaro Aso, Akira Kawauchi, Shigeki Fujitani, Taku Oshima, Hideaki Kato, Kohei Ota, Hiroshi Kamijo, Tomohiro Asahi, and et al. 2025. "Effects of Long COVID in Patients with Severe Coronavirus Disease 2019 on Long-Term Functional Impairments: A Post Hoc Analysis Focusing on Patients Admitted to the ICU in the COVID-19 Recovery Study II" Healthcare 13, no. 4: 394. https://doi.org/10.3390/healthcare13040394
APA StyleHatakeyama, J., Nakamura, K., Aso, S., Kawauchi, A., Fujitani, S., Oshima, T., Kato, H., Ota, K., Kamijo, H., Asahi, T., Muto, Y., Hori, M., Iba, A., Hosozawa, M., & Iso, H. (2025). Effects of Long COVID in Patients with Severe Coronavirus Disease 2019 on Long-Term Functional Impairments: A Post Hoc Analysis Focusing on Patients Admitted to the ICU in the COVID-19 Recovery Study II. Healthcare, 13(4), 394. https://doi.org/10.3390/healthcare13040394